These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22975107)

  • 21. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation therapy for prostate cancer.
    Sharifi N; Gulley JL; Dahut WL
    JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Boué A; Joly F; Lequesne J; Lange M
    Cancer; 2024 Jun; 130(12):2120-2138. PubMed ID: 38306301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociation of event-based prospective memory and time-based prospective memory in patients with prostate cancer receiving androgen-deprivation therapy: a neuropsychological study.
    Yang J; Zhong F; Qiu J; Cheng H; Wang K
    Eur J Cancer Care (Engl); 2015 Mar; 24(2):198-204. PubMed ID: 25711542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms.
    Grunfeld EA; Halliday A; Martin P; Drudge-Coates L
    Cancer Nurs; 2012; 35(1):63-9. PubMed ID: 21558849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training.
    Mundell NL; Daly RM; Macpherson H; Fraser SF
    Endocr Relat Cancer; 2017 Apr; 24(4):R145-R155. PubMed ID: 28209634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
    Mohile SG; Lacy M; Rodin M; Bylow K; Dale W; Meager MR; Stadler WM
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):152-9. PubMed ID: 20656210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.
    Hara N; Nishiyama T; Takizawa I; Saito T; Kitamura Y; Takahashi K
    Urology; 2010 Jun; 75(6):1441-5. PubMed ID: 20110105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.
    Siebert AL; Lapping-Carr L; Morgans AK
    Eur Urol Focus; 2020 Nov; 6(6):1170-1179. PubMed ID: 32690473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
    Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer.
    Ross A; Brewer K; Hudgens S; Brown B; Fallick M; de Paauw-Holt S; Arondekar B; Clegg J; Hunsche E
    Adv Ther; 2024 Aug; 41(8):3076-3088. PubMed ID: 38861216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management.
    Gudenkauf LM; Gray S; Gonzalez BD; Sachdeva A; Autio K
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433126. PubMed ID: 38788186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New-onset psychosis following androgen deprivation therapy for prostate cancer.
    Bernad DM; Dal Pra A; Baule C; Frey BN; Faria S
    Can J Urol; 2013 Aug; 20(4):6868-70. PubMed ID: 23930615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.